3α,7β-dihydroxy-25,26-bis-homo-5β-cholan-26-oic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3α,7β-dihydroxy-25,26-bis-homo-5β-cholan-26-oic acid
• 英文别名: Dihomoursodeoxycholic acid；(6R)-6-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid
• 化学式: C₂₆H₄₄O₄
• 分子量: 420.633
• InChiKey: ISELACRIJKHUTE-LBSADWJPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3α,7β-dihydroxy-25,26-bis-homo-5β-cholan-26-oic acid 在 吡啶 、 水 、 三氟乙酸 、 三氟乙酸酐 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 33.0h， 生成 高乌苏基脱氧胆酸
  参考文献：
  名称：

  [EN] BILE ACID DERIVATIVE HAVING ANTIVIRAL EFFECT ON HEPATITIS B VIRUS
  [FR] DÉRIVÉ D'ACIDE BILIAIRE AYANT UN EFFET ANTIVIRAL SUR LE VIRUS DE L'HÉPATITE B
  [JA] Ｂ型肝炎ウイルスに対する抗ウイルス効果を有する胆汁酸誘導体

  摘要：

  本発明は、Ｂ型肝炎ウイルスに対する抗ウイルス効果を有する胆汁酸誘導体を提供することを目的とする。具体的には、以下の式Ｉで表される胆汁酸誘導体又はその薬理学的に許容できる塩を有効成分として含む、Ｂ型肝炎ウイルス（ＨＢＶ）の感染を予防、又はＨＢＶ感染に起因する肝炎、肝硬変、又は肝臓がんを治療又は予防するための医薬組成物： （Ｉ）　（ここで、各々独立して Ｒ１はα－ＯＨ基、β－ＯＨ基、α－ＯＳＯ３Ｈ基、または＝Ｏであり； Ｒ２は、－Ｈ、α－ＯＨ基、β－ＯＨ基、α－ＣＨ３基であり； Ｒ３は、－Ｈ、α－ＯＨ基、β－ＯＨ基、またはβ－ＯＳＯ３Ｈ基であり； Ｒ４は、－Ｈ又はα－ＯＨ基であり； Ｒ５は、－［ＣＨ（ＣＨ３）］ｍ－（ＣＯＮＨ）Ｏ－［ＣＨ（ＯＨ）］ｐ－（ＣＨ２）ｑ－Ｒ７－｛ＣＨ［（ＣＨ２）ｎＯＨ］｝ｒ－（ＣＨ２）ｓ－Ｒ８基であり；　ｏは０または１であって、　ｏが０の場合、Ｒ７は結合であり、　ｏが１の場合、Ｒ７は結合、－Ｃ６Ｈ４－、－Ｃ６Ｈ５－、－ＣＨ（ＣＯＯＨ）－、または－ＣＨ（ＣＨ２ＯＨ）－であり；　ｍ、ｐ、ｑ、ｒ、ｓ、ｎは独立して０、１、２、３、４、及び５から選択され；　Ｒ８は、－ＯＳＯ３Ｈ基、－ＳＯ３Ｈ基、－ＯＨ基、または－ＣＯＯＨ基であり； Ｒ６は、α－Ｈ又はβ－Ｈである） を提供する。

  公开号：

  WO2022225035A1
• 作为产物：
  描述：

  methyl 3α,7β-di(tert-butyldimethylsilyloxy)-5β-cholan-24-oate 在 盐酸 、 锂硼氢 、 草酰氯 、 5% Pd(OH)2/C 、 氢气 、 二甲基亚砜 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 5.5h， 生成 3α,7β-dihydroxy-25,26-bis-homo-5β-cholan-26-oic acid
  参考文献：
  名称：

  [EN] CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES
  [FR] DÉRIVÉS DE CHOLANE À UTILISER DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES MÉDIÉES PAR FXR ET TGR5/GPBAR1

  摘要：

  公开号：

  WO2015181275A8

文献信息

• Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
  申请人：SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.

  公开号：US10301303B2

  公开（公告）日：2019-05-28

  The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders. The compounds and pharmaceutical compositions of the invention can be utilized to treat various diseases or disorders, such as diabetes, diabetic complications, dyslipidemia, hyperlipidemia, obesity, metabolic syndromes, pre-diabetes, atherosclerosis, heart diseases, neurodegenerative diseases, sarcopenia, muscle atrophy, inflammation, cancer and liver diseases and conditions such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. The compounds of this invention are also useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases.

  本发明提供了小檗碱与药理活性有机酸结合的各种新型组合物及其用于治疗各种疾病或失调的相关方法。本发明进一步提供了由小檗碱和药理活性有机酸制备的和由熊去氧胆酸和药理活性有机碱制备的各种新型化合物及其药物组合物，以及它们在治疗和/或预防各种疾病或紊乱中的制备和治疗方法。本发明的化合物和药物组合物可用于治疗各种疾病或失调，如糖尿病、糖尿病并发症、血脂异常、高脂血症、肥胖症、代谢综合征、糖尿病前期、动脉粥样硬化、心脏病、神经退行性疾病、骨质疏松症等、神经退行性疾病、肌肉疏松症、肌肉萎缩、炎症、癌症和肝脏疾病，如脂肪肝、非酒精性脂肪肝、非酒精性脂肪性肝炎、胆汁淤积性肝病或肝脏移植物抗宿主疾病。本发明的化合物还可用于改善慢性病毒相关性肝病和酒精相关性肝病的肝功能。
• Pharmaceutical composition comprising berberine ursodeoxycholic acid salt for the treatment of various diseases or disorders
  申请人：SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.

  公开号：US10988471B2

  公开（公告）日：2021-04-27

  The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders. The compounds and pharmaceutical compositions of the invention can be utilized to treat various diseases or disorders, such as diabetes, diabetic complications, dyslipidemia, hyperlipidemia, obesity, metabolic syndromes, pre-diabetes, atherosclerosis, heart diseases, neurodegenerative diseases, sarcopenia, muscle atrophy, inflammation, cancer and liver diseases and conditions such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. The compounds of this invention are also useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases.

  本发明提供了小檗碱与药理活性有机酸结合的各种新型组合物及其用于治疗各种疾病或失调的相关方法。本发明进一步提供了由小檗碱和药理活性有机酸制备的和由熊去氧胆酸和药理活性有机碱制备的各种新型化合物及其药物组合物，以及它们在治疗和/或预防各种疾病或紊乱中的制备和治疗方法。本发明的化合物和药物组合物可用于治疗各种疾病或失调，如糖尿病、糖尿病并发症、血脂异常、高脂血症、肥胖症、代谢综合征、糖尿病前期、动脉粥样硬化、心脏病、神经退行性疾病、骨质疏松症等、神经退行性疾病、肌肉疏松症、肌肉萎缩、炎症、癌症和肝脏疾病，如脂肪肝、非酒精性脂肪肝、非酒精性脂肪性肝炎、胆汁淤积性肝病或肝脏移植物抗宿主疾病。本发明的化合物还可用于改善慢性病毒相关性肝病和酒精相关性肝病的肝功能。
• [EN] CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES<br/>[FR] DÉRIVÉS DE CHOLANE À UTILISER DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES MÉDIÉES PAR FXR ET TGR5/GPBAR1
  申请人：BAR PHARMACEUTICALS S R L

  公开号：WO2015181275A8

  公开（公告）日：2016-02-18
• CONJUGATE COMPOUNDS OF URSODEOXYCHOLIC, BERBERINE OR L-CARNITINE, AND COMPOSITIONS AND METHODS THEREOF
  申请人：SHENZHEN HJGHTIDE-BIOPHARMAGEUTiCAL, LTD.

  公开号：US20180050048A1

  公开（公告）日：2018-02-22

  The invention provides novel conjugate compounds having at least one of a moiety derived from ursodeoxycholic acid, or eicosapentaenoic acid, or docosahexaenoic acid, or rhein, or R-(+)-α-lipoic acid, or ursolic acid, or corosolic acid, or hydroxycitric acid, or cinnamic acid, or cholic acid, or oleanolic acid, or salicylic acid, or betulinic acid, or chlorogenic acid, or caffeic acid, or bassic acid, or acetyl L-carnitine, or S-allyl cysteine sulphoxide, or S-methyl cysteine sulfoxide, or pantothenic acid, or ascorbic acid, or retinoic acid, or nicotinic acid, or biotin, or a derivative or analog thereof, and a moiety derived from berberine or L-carnitine or metformin or unsaturated fatty acid, or a derivative or analog thereof. The invention also relates to pharmaceutical compositions, methods of preparation and use of these conjugates in treating and/or preventing, for example, liver diseases or disorders, various diabetes, diabetic complications, dyslipidemia, obesity, metabolic syndromes, pre-diabetes, muscle atrophy, inflammation, and cancers. The compounds of this invention are also useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases.
• BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF
  申请人：SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.

  公开号：US20190211007A1

  公开（公告）日：2019-07-11

  The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders. The compounds and pharmaceutical compositions of the invention can be utilized to treat various diseases or disorders, such as diabetes, diabetic complications, dyslipidemia, hyperlipidemia, obesity, metabolic syndromes, pre-diabetes, atherosclerosis, heart diseases, neurodegenerative diseases, sarcopenia, muscle atrophy, inflammation, cancer and liver diseases and conditions such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. The compounds of this invention are also useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases.